Prior research has established a correlation between the transcriptional silencing of RARRES1 in esophageal, gastric, endometrial, and prostate cancers and epigenetic inactivation resulting from promoter hypermethylation23,28,29,33. This evidence concerns the gene RARRES1 and Familial prostate cancer.